Literature DB >> 19874666

Prevalence of gabapentin in impaired driving cases in Washington State in 2003-2007.

Brianna L Peterson1.   

Abstract

Gabapentin (Neurontin) is an antiepileptic drug commonly prescribed for pain treatment. In the past 15 years, indications for gabapentin have been increasing even though the complete mechanism of action is unknown. Side effects include somnolence, dizziness, ataxia, nystagmus, and fatigue. This study reviewed all cases positive for gabapentin submitted to the Washington State Toxicology Laboratory between January 2003 and December 2007. The concentrations of gabapentin in blood from impaired driving cases (n = 137) ranged from < 2.0 to 24.7 mg/L with a mean of 8.4 +/- 5.4 mg/L and a median of 7.0 mg/L. The driving population was 50% male with a mean age of 43.0 +/- 10.9 years (range 23-73). Of the cases studied, only 7% were positive for gabapentin alone with the remaining 93% indicative of polydrug use. Drug Recognition Expert reports from four cases in which the only drug detected likely to be causing impairment was gabapentin were examined. These reports demonstrated that subjects may exhibit psychophysical indicators of a central nervous system depressant (e.g., horizontal gaze nystagmus, poor performance on standardized field sobriety tests) with clinical indicators (e.g., dilated pupils, low body temperature, and elevated pulse and blood pressure) that are not consistent with a depressant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874666     DOI: 10.1093/jat/33.8.545

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  7 in total

1.  A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.

Authors:  Rachel Vickers Smith; Elaine M Boland; April M Young; Michelle R Lofwall; Alexa Quiroz; Michele Staton; Jennifer R Havens
Journal:  Psychol Addict Behav       Date:  2017-12-14

2.  Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.

Authors:  Rachel Vickers-Smith; Jiangwen Sun; Richard J Charnigo; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2019-11-02       Impact factor: 4.492

Review 3.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

4.  Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.

Authors:  Michael D Stein; Shannon R Kenney; Bradley J Anderson; Micah T Conti; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2019-12-13

5.  Evaluation of the effect of pregabalin on simulated driving ability using a driving simulator in healthy male volunteers.

Authors:  Tomoaki Tujii; Win Thiri Kyaw; Hirotaka Iwaki; Noriko Nishikawa; Masahiro Nagai; Madoka Kubo; Masahiro Nomoto
Journal:  Int J Gen Med       Date:  2014-01-29

Review 6.  Management of neuropathic pain.

Authors:  Noriko Nishikawa; Masahiro Nomoto
Journal:  J Gen Fam Med       Date:  2017-04-12

7.  Transient Positive Horizontal Head Impulse Test in Pregabalin Intoxication.

Authors:  Seong-Hae Jeong; Yong Soo Kim; Ju-Hoen Lee; Hyunjin Jo; Ae Young Lee; Jae-Moon Kim
Journal:  J Epilepsy Res       Date:  2015-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.